Cargando…
Assessment in the Survival Outcome After Transarterial Chemoembolization Combined with Cryoablation for Hepatocellular Carcinoma (Diameter > 4cm) Based on the Albumin-Bilirubin Grade and Platelet-Albumin-Bilirubin grade: A Preliminary Study
OBJECTIVE: Based on the albumin-bilirubin (ALBI) and platelet-albumin-bilirubin (PALBI) grade to assess the long-term outcomes of patients with large hepatocellular carcinoma (HCC) after transarterial chemoembolization combined with cryoablation (TACE-CRA). MATERIALS AND METHODS: We studied 86 patie...
Autores principales: | Huang, Zhimei, Zuo, Mengxuan, Ni, Jiayan, Gu, Yangkui, Zhang, Tianqi, Jiang, Yiquan, Zhuo, Shuiqing, An, Chao, Huang, Jinhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049291/ https://www.ncbi.nlm.nih.gov/pubmed/32158269 http://dx.doi.org/10.2147/CMAR.S234116 |
Ejemplares similares
-
Prognostic Performance of Albumin–Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib
por: Zhong, Bin-Yan, et al.
Publicado: (2020) -
To determine the prognostic value of the albumin–bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Khalid, Muhammad Ali, et al.
Publicado: (2019) -
Changes in prognostic factors for patients with hepatocellular carcinoma underwent transarterial chemoembolization with the transition of the time: Child-Pugh class, Albumin-Bilirubin grade, and then
por: Kawaguchi, Takumi, et al.
Publicado: (2020) -
Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma
por: Wang, Zhexuan, et al.
Publicado: (2020) -
Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC
por: Zhao, Shoujie, et al.
Publicado: (2020)